KR100689943B1 - 당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물 - Google Patents

당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물 Download PDF

Info

Publication number
KR100689943B1
KR100689943B1 KR1020017008102A KR20017008102A KR100689943B1 KR 100689943 B1 KR100689943 B1 KR 100689943B1 KR 1020017008102 A KR1020017008102 A KR 1020017008102A KR 20017008102 A KR20017008102 A KR 20017008102A KR 100689943 B1 KR100689943 B1 KR 100689943B1
Authority
KR
South Korea
Prior art keywords
group
alkyl
substituted
aryl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017008102A
Other languages
English (en)
Korean (ko)
Other versions
KR20010099942A (ko
Inventor
마크 디. 에리온
폴 반포엘제
Original Assignee
메타베이시스 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메타베이시스 테라퓨틱스, 인크. filed Critical 메타베이시스 테라퓨틱스, 인크.
Publication of KR20010099942A publication Critical patent/KR20010099942A/ko
Application granted granted Critical
Publication of KR100689943B1 publication Critical patent/KR100689943B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020017008102A 1998-12-24 1999-12-22 당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물 Expired - Fee Related KR100689943B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11471898P 1998-12-24 1998-12-24
US60/114,718 1998-12-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020067022095A Division KR20060114724A (ko) 1998-12-24 1999-12-22 당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물

Publications (2)

Publication Number Publication Date
KR20010099942A KR20010099942A (ko) 2001-11-09
KR100689943B1 true KR100689943B1 (ko) 2007-03-08

Family

ID=22357016

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020017008102A Expired - Fee Related KR100689943B1 (ko) 1998-12-24 1999-12-22 당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물
KR1020067022095A Ceased KR20060114724A (ko) 1998-12-24 1999-12-22 당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물
KR1020077008649A Ceased KR20070046210A (ko) 1998-12-24 1999-12-22 당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020067022095A Ceased KR20060114724A (ko) 1998-12-24 1999-12-22 당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물
KR1020077008649A Ceased KR20070046210A (ko) 1998-12-24 1999-12-22 당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물

Country Status (25)

Country Link
EP (1) EP1143955B1 (enExample)
JP (1) JP2003515523A (enExample)
KR (3) KR100689943B1 (enExample)
CN (3) CN101164618A (enExample)
AT (1) ATE300288T1 (enExample)
AU (1) AU771039B2 (enExample)
BR (1) BR9917005A (enExample)
CA (1) CA2354053A1 (enExample)
CZ (1) CZ20012353A3 (enExample)
DE (1) DE69926400T2 (enExample)
DK (1) DK1143955T3 (enExample)
ES (1) ES2246586T3 (enExample)
HK (1) HK1046863B (enExample)
HU (1) HUP0402506A3 (enExample)
ID (1) ID30237A (enExample)
IL (2) IL143569A0 (enExample)
MX (1) MXPA01006511A (enExample)
NO (1) NO20013115L (enExample)
NZ (1) NZ512219A (enExample)
PL (1) PL352756A1 (enExample)
PT (1) PT1143955E (enExample)
RU (2) RU2227749C2 (enExample)
SK (1) SK9172001A3 (enExample)
WO (1) WO2000038666A2 (enExample)
ZA (1) ZA200105016B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014099804A1 (en) 2012-12-18 2014-06-26 Huntair, Inc. Air filter assembly

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE69910045T2 (de) 1998-09-09 2004-04-22 Metabasis Therapeutics Inc., San Diego Neue heteroaromatische fructose 1,6-bisphosphatase inhibitoren
AU784370B2 (en) 1999-12-22 2006-03-23 Metabasis Therapeutics, Inc. Novel bisamidate phosphonate prodrugs
MXPA02008722A (es) 2000-03-08 2004-05-05 Metabasis Therapeutics Inc Inhibidores novedosos de aril fructosa-1,6-bisfosfatasa.
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
HUP0301830A3 (en) * 2000-07-06 2007-10-29 Metabasis Therapeutics Inc Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
CA2429426A1 (en) 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Isoxazole derivatives
JP4476811B2 (ja) 2002-05-13 2010-06-09 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびそのアナログの新規ホスホン酸系プロドラッグ
JP4332496B2 (ja) 2002-05-13 2009-09-16 メタバシス・セラピューティクス・インコーポレイテッド Ｐｍｅａおよびｐｍｐａ環生成合成
AU2003264256A1 (en) * 2002-09-04 2004-03-29 Dsm Ip Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
UA80991C2 (en) 2002-10-07 2007-11-26 Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes
MXPA05008335A (es) * 2003-02-11 2006-05-04 Vernalis Cambridge Ltd Compuestos de isoxazol como inhibidores de las proteinas de choque por calor.
CA2551611C (en) * 2003-12-26 2013-06-25 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives for treating or preventing parkinson's disease
KR20070053764A (ko) * 2004-08-18 2007-05-25 메타베이시스 테라퓨틱스, 인크. 프럭토스 1,6-비스포스파타제의 신규한 티아졸 억제제들
TW200633720A (en) * 2004-12-13 2006-10-01 Sankyo Co Medicinal composition for diabetic
TW200633702A (en) * 2004-12-15 2006-10-01 Sankyo Co Medicinal composition containing fbpase inhibitor
US20090227493A1 (en) * 2005-05-27 2009-09-10 Daiichi Sankyo Company, Limited Combined drug for treating diabetes
EP1894930A4 (en) 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE
EP2089017A2 (en) 2006-11-02 2009-08-19 Aestus Therapeutics, Inc. Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
CN103665043B (zh) 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
WO2015123352A1 (en) 2014-02-13 2015-08-20 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
CN105481896A (zh) * 2015-12-03 2016-04-13 浙江大学 一种地马格列的制备方法
CN113416739B (zh) * 2021-06-24 2022-04-19 黑龙江八一农垦大学 鲁氏酵母菌基因在提高微生物产hdmf的产量中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968790A (en) * 1988-08-12 1990-11-06 American Cyanamid Company Antidiabetic phosphates
JPH03157377A (ja) * 1988-11-18 1991-07-05 Takeda Chem Ind Ltd チオ尿素誘導体及びａｇｅ生成阻害剤
DE69014562T2 (de) * 1989-01-24 1995-06-22 Gensia Pharma Verfahren und verbindungen zur verabreichung von aica ribosiden und zur erniedrigung des blutglucose gehaltes.
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
WO1998039342A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
ZA981936B (en) * 1997-03-07 1999-09-06 Metabasis Therapeutics Inc Novel benzimidazole inhibitors of fructose 1,6-bisphosphatase.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014099804A1 (en) 2012-12-18 2014-06-26 Huntair, Inc. Air filter assembly

Also Published As

Publication number Publication date
WO2000038666A3 (en) 2001-11-29
WO2000038666A2 (en) 2000-07-06
CN1714866A (zh) 2006-01-04
HK1046863B (zh) 2008-07-25
KR20070046210A (ko) 2007-05-02
PL352756A1 (en) 2003-09-08
IL143569A (en) 2006-06-11
HK1046863A1 (zh) 2003-01-30
CA2354053A1 (en) 2000-07-06
CN101164618A (zh) 2008-04-23
SK9172001A3 (en) 2002-04-04
DK1143955T3 (da) 2005-11-14
RU2003132054A (ru) 2005-04-20
CZ20012353A3 (cs) 2001-12-12
IL143569A0 (en) 2002-04-21
DE69926400D1 (de) 2005-09-01
AU771039B2 (en) 2004-03-11
CN100352505C (zh) 2007-12-05
ZA200105016B (en) 2002-09-19
AU2058300A (en) 2000-07-31
DE69926400T2 (de) 2006-05-24
BR9917005A (pt) 2002-04-02
NO20013115D0 (no) 2001-06-21
KR20010099942A (ko) 2001-11-09
HUP0402506A3 (en) 2007-05-29
CN1350466A (zh) 2002-05-22
EP1143955A3 (en) 2002-08-28
ES2246586T3 (es) 2006-02-16
MXPA01006511A (es) 2004-03-19
NZ512219A (en) 2004-12-24
ATE300288T1 (de) 2005-08-15
ID30237A (id) 2001-11-15
EP1143955B1 (en) 2005-07-27
RU2227749C2 (ru) 2004-04-27
KR20060114724A (ko) 2006-11-07
JP2003515523A (ja) 2003-05-07
EP1143955A2 (en) 2001-10-17
NO20013115L (no) 2001-08-24
HUP0402506A2 (hu) 2005-04-28
PT1143955E (pt) 2005-11-30

Similar Documents

Publication Publication Date Title
KR100689943B1 (ko) 당뇨병 치료용 ＦＢＰａｓｅ 억제제 및 인슐린 증감제의조합물
US20080004226A1 (en) Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes
KR100818845B1 (ko) 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
KR100875335B1 (ko) 신규 비스아미데이트 포스포네이트 프로드러그
KR100854851B1 (ko) 당뇨병 치료에 유용한 ＦＢＰａｓｅ 억제제와 항당뇨제의조합물
EP1552850A2 (en) A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
HK1075622A (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
AU2003242500C1 (en) Novel Heteroaromatic Inhibitors of Fructose 1,6-bisphosphatase
MXPA01002542A (en) Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100227

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100227

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000